Any Idea why trading was halted?
The better articles showed this useful information;
"Summary of Phase 2 Study Design and Interim Results
This study was designed to determine the safety, pharmacokinetics, and efficacy of different dosing regimens containing ODV and AL-335, with or without SMV, in treatment-naïve patients with GT1 HCV infection for treatment durations of eight or six weeks."
===============
My opinion on this is that they got great results treating ONLY those easiest to treat treatment naive patients.
For me, the results showed that they needed all 3 compounds to be effective. Simeprevir isn't particularly effective on G-3s or RAVs (or so I think), so what do they really have here;
(answer)....a possibly genotype 1 treatment for those without tougher to treat resistant RAV's the occur through exposure to past PI treatments, and which occur naturally in HCV infected populations. I think it will/ could do much worse on TX experienced groups, it won't be pan-genotypic IMHO.
In addition they have one discontinuation due to an adverse event thought to be treatment related,
ACHN is up, but I don't feel these are great results.
To my way of thinking it could never compete with Gilead's Epclusa or Abbvie/Enta's next gen, currently in phase 3.
AI
Market Data 
Markets 
